TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7871099

Group type: EXPERIMENTAL
Intervention: Standard cigarette after 1 hour deprivation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard cigarette after 12 hours deprivation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham smoking after 1 hour deprivation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham smoking after 12 hours deprivation
Number of subjects: 0
Study: 3066880

Group type: EXPERIMENTAL
Intervention: First-generation cephalosporin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Third-generation cephalosporin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early bone grafting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soft tissue coverage procedures
Number of subjects: 0
Study: 1858666

Group type: EXPERIMENTAL
Intervention: Racal Airstream helmet respirator
Number of subjects: 19

Group type: COMPARATOR
Intervention: 3M 9906 disposable mask
Number of subjects: 19
Study: 137921

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide via metered-dose inhaler
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 20
Study: 31082417

Group type: EXPERIMENTAL
Intervention: Galantamine (8 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 28876367

Group type: EXPERIMENTAL
Intervention: Xuezhikang (1200 mg/day, orally)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 25877855

Group type: EXPERIMENTAL
Intervention: Ramucirumab plus FOLFIRI
Number of subjects: 1072

Group type: COMPARATOR
Intervention: Placebo plus FOLFIRI
Number of subjects: 1072
Study: 23841259

Group type: EXPERIMENTAL
Intervention: YJQR combined endocrine therapy
Number of subjects: 44
Study: 21911629

Group type: EXPERIMENTAL
Intervention: Directive group (received explanations plus advice)
Number of subjects: 2944

Group type: EXPERIMENTAL
Intervention: Nondirective group (received explanations)
Number of subjects: 2944

Group type: COMPARATOR
Intervention: Control group (received no explanation)
Number of subjects: 2944
Study: 19958861

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 16715347

Group type: EXPERIMENTAL
Intervention: Experimental intervention (training in HIV/AIDS, STI, and TB prevention over 3.5 days with supervisory follow-up)
Number of subjects: 233

Group type: COMPARATOR
Intervention: No intervention (control condition)
Number of subjects: 233
Study: 15490272

Group type: EXPERIMENTAL
Intervention: Exercise intervention group (n=22)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (n=22)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Exercise intervention group
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study: 11228592

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (plain and enteric-coated formulations)
Number of subjects: 12105

Group type: EXPERIMENTAL
Intervention: Enteric-coated formulations of aspirin
Number of subjects: 12105

Group type: EXPERIMENTAL
Intervention: Plain aspirin
Number of subjects: 12105

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin with high-dose NSAIDs
Number of subjects: 12105

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin with low-medium doses of NSAIDs
Number of subjects: 12105

Group type: EXPERIMENTAL
Intervention: First two months of treatment with low-dose aspirin
Number of subjects: 12105
Study: 9334096

Group type: EXPERIMENTAL
Intervention: Intragastric balloon implantation with a 1500 kcal diet (Group I)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intragastric balloon implantation with intensive additional therapy by a dietitian (Group II)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham implantation with intensive additional therapy by a dietitian (Group III)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group with diet advice only (Group IV)
Number of subjects: 40
Study: 8487488

Group type: EXPERIMENTAL
Intervention: Theophylline 10 mg/kg body weight
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Theophylline 20 mg/kg body weight
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Theophylline 10 mg/kg and 20 mg/kg body weight
Number of subjects: 16
Study: 3326114

Group type: EXPERIMENTAL
Intervention: Zopiclone 5.0 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zopiclone 10.0 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31876036

Group type: EXPERIMENTAL
Intervention: Nurse-led distress screening intervention (NDTI)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 194
Study: 31623132

Group type: EXPERIMENTAL
Intervention: 0.556 W·s‐1 RAMP incremental test
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.278 W·s‐1 RAMP incremental test
Number of subjects: 20
Study: 28929950

Group type: EXPERIMENTAL
Intervention: High theoretical fidelity condition
Number of subjects: 56

Group type: COMPARATOR
Intervention: Low theoretical fidelity condition
Number of subjects: 56
Study: 26604649

Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) therapy
Number of subjects: 231
Study: 23182378

Group type: EXPERIMENTAL
Intervention: DreamLens (Hanita Lenses Investments, Hanita, Israel)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Rinehart-Reeves (R&R; Danker Laboratories, Sarasota, FL)
Number of subjects: 22
Study: 21199833

Group type: EXPERIMENTAL
Intervention: Satavaptan 50 mg/day
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Satavaptan 25 mg/day
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Satavaptan 25 mg/day in CHF patients
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Satavaptan 50 mg/day in CHF patients
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo in CHF patients
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Satavaptan therapy
Number of subjects: 118
Study: 18084782

Group type: EXPERIMENTAL
Intervention: ACDF with cervical intervertebral fusion cage or Cloward procedure
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Short-term outcome data
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Neck Disability Index (NDI)
Number of subjects: 95
Study: 17135984

Group type: EXPERIMENTAL
Intervention: Combined treatment (FLX and CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0
Study: 12374713

Group type: EXPERIMENTAL
Intervention: Propofol (high concentration target)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Propofol (low concentration target)
Number of subjects: 12
Study: 10434828

Group type: EXPERIMENTAL
Intervention: Adenosine 100 micrograms kg‐1 min‐1
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 8
Study: 8640147

Group type: EXPERIMENTAL
Intervention: Alutard SQ
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 37
Study: 2273519

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Azathioprine and Methotrexate (MTX)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Group 1 (Azathioprine or MTX)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Group 2 (Adverse effect dropout)
Number of subjects: 146
Study: 532919

Group type: EXPERIMENTAL
Intervention: Chloroprocaine hydrochloride 2%
Number of subjects: 24

Group type: COMPARATOR
Intervention: Bupivacaine hydrochloride 0.375%
Number of subjects: 24
Study: 29370261

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 26670938

Group type: EXPERIMENTAL
Intervention: Fast Track intervention
Number of subjects: 891
Study: 23884322

Group type: EXPERIMENTAL
Intervention: Click City (®) : Tobacco program
Number of subjects: 2322

Group type: COMPARATOR
Intervention: Usual Curriculum
Number of subjects: 2322
Study: 22550837

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 microg/Kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fentanyl 0.5 microg/Kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 40
Study: 20458909

Group type: EXPERIMENTAL
Intervention: Ear-acupuncture
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Scalp-acupuncture
Number of subjects: 90

Group type: COMPARATOR
Intervention: Body-acupuncture
Number of subjects: 90
Study: 17603143

Group type: EXPERIMENTAL
Intervention: Yamax Digiwalker step counts
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Accelerometer data for MVPA
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Daily step count equating to 1-hr MVPA engagement
Number of subjects: 129
Study: 16089149

Group type: EXPERIMENTAL
Intervention: Angong niuhuang pill (ANP)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 97
Study: 12391947

Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 460

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 460
Study: 10089851

Group type: EXPERIMENTAL
Intervention: EPS/ICD strategy
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Conventional strategy
Number of subjects: 1200
Study: 7801868

Group type: EXPERIMENTAL
Intervention: Hirudin (dose 1: 0.15 mg/kg bolus + 0.05 mg/kg/hour infusion)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Hirudin (dose 2: 0.3 mg/kg bolus + 0.1 mg/kg/hour infusion)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Hirudin (dose 3: 0.6 mg/kg bolus + 0.2 mg/kg/hour infusion)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Heparin (5,000 U bolus + 1,000 U/hour infusion)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Hirudin (dose 1)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Hirudin (dose 2)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Hirudin (dose 3)
Number of subjects: 193
Study: 2182703

Group type: EXPERIMENTAL
Intervention: Géméprost (vaginal suppository)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sulprostone (intravenous infusion)
Number of subjects: 32
Study: 6154345

Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with chemotherapy (bleomycin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two-phase treatment modality (bleomycin or BUdR combined with radiotherapy)
Number of subjects: 0
Study: 31974133

Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy (295 patients)
Number of subjects: 587

Group type: COMPARATOR
Intervention: Placebo (292 patients)
Number of subjects: 587
Study: 31046879

Group type: EXPERIMENTAL
Intervention: 3 anti-waterpipe PSAs
Number of subjects: 45

Group type: COMPARATOR
Intervention: 3 control videos
Number of subjects: 45
Study: 28972236

Group type: EXPERIMENTAL
Intervention: Post-discharge individualized nutritional intervention (protein and energy enriched diet, oral nutritional supplements, vitamin D3/calcium supplement, telephone counseling by a dietitian)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Usual care regimen (control group)
Number of subjects: 210
Study: 26370520

Group type: EXPERIMENTAL
Intervention: MTA
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 3Mixtatin
Number of subjects: 83

Group type: COMPARATOR
Intervention: 3Mix
Number of subjects: 83

Group type: COMPARATOR
Intervention: simvastatin
Number of subjects: 83
Study: 25128176

Group type: EXPERIMENTAL
Intervention: Calibrated delivery drape
Number of subjects: 900

Group type: COMPARATOR
Intervention: Indirect method (shallow bedpan)
Number of subjects: 900
Study: 22459620

Group type: EXPERIMENTAL
Intervention: Protein (PRO + CHO) beverage consumed immediately after exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carbohydrate (CHO) beverage consumed immediately after exercise
Number of subjects: 0
Study: 19675862

Group type: EXPERIMENTAL
Intervention: 1% diatrizoate meglumine (Group 1, n=25)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 2.5% mannitol (Group 2, n=20)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Water (Group 3, n=16)
Number of subjects: 61
Study: 17954941

Group type: EXPERIMENTAL
Intervention: Combined mass media campaign
Number of subjects: 200

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 200
Study: 16078673

Group type: EXPERIMENTAL
Intervention: rhGH 4 IU
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: rhGH 8 IU
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 40
Study: 11912355

Group type: EXPERIMENTAL
Intervention: Latanoprost once daily
Number of subjects: 379

Group type: COMPARATOR
Intervention: Brimonidine twice daily
Number of subjects: 379

Group type: COMPARATOR
Intervention: Latanoprost vs Brimonidine
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 379
Study: 9767193

Group type: EXPERIMENTAL
Intervention: Early antiplatelet therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of aspirin and dipyridamole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of antiplatelet agents (e.g. aspirin and clopidogrel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of antiplatelet agents and oral anticoagulants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of antithrombotic and cholesterol-lowering medications (statins)
Number of subjects: 0
Study: 1995788

Group type: EXPERIMENTAL
Intervention: Orally administered deuterated pyridoxine (PN)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Orally administered deuterated pyridoxine-5'-beta-D-glucoside (PN-glucoside)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Intravenously administered pyridoxine-5'-beta-D-glucoside (PN-glucoside)
Number of subjects: 5
Study: 6516515

Group type: EXPERIMENTAL
Intervention: Ionic low osmolar ioxaglat (Hexabrix)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Non-ionic low osmolar iopamidol (Solutrast 370)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional ionic and high-osmolar ioxitalamat (Telebrix 350)
Number of subjects: 80
Study: 30700347

Group type: EXPERIMENTAL
Intervention: Chlorquinaldol‐promestriene vaginal tablets
Number of subjects: 98

Group type: COMPARATOR
Intervention: Opin suppositories
Number of subjects: 98
Study: 29791690

Group type: EXPERIMENTAL
Intervention: Upper removable appliance with digital springs (Group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Resin-reinforced glass ionomer cement bite pads on the lower first molars (Group 2)
Number of subjects: 30
Study: 26523433

Group type: EXPERIMENTAL
Intervention: PUC‐ETT
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: PUC‐CASS‐ETT
Number of subjects: 102

Group type: COMPARATOR
Intervention: PVC‐ETT
Number of subjects: 102
Study: 24625322

Group type: EXPERIMENTAL
Intervention: PegIFNα (type Y peginterferon α‐2b 90 μg, 135 μg, 180 μg and PegIFNα‐2a 180 μg, respectively, once a week) and ribavirin (< 75 kg, 1000 mg daily and ≥ 75 kg, 1200 mg daily) for 48 weeks
Number of subjects: 32
Study: 22388710

Group type: EXPERIMENTAL
Intervention: Corticosteroids plus pentoxifylline (prednisolone 40 mg/day plus pentoxifylline 400 mg thrice/day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Corticosteroids alone (prednisolone 40 mg/day)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Corticosteroids plus pentoxifylline
Number of subjects: 70

Group type: COMPARATOR
Intervention: Corticosteroids alone
Number of subjects: 70
Study: 20820127

Group type: EXPERIMENTAL
Intervention: Transitional care program
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 128
Study: 18553045

Group type: EXPERIMENTAL
Intervention: New appendicitis inflammatory response score
Number of subjects: 545

Group type: COMPARATOR
Intervention: Alvarado score
Number of subjects: 545
Study: 16822121

Group type: EXPERIMENTAL
Intervention: Task-cuing with varied cue-stimulus intervals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Task-cuing with low probability of task change
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition based on previous studies by Logan and Bundesen
Number of subjects: 0
Study: 12814685

Group type: EXPERIMENTAL
Intervention: 250mg Levofloxacin p.o. given approximately 60 minutes prior to ureteroscopy
Number of subjects: 113

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 113
Study: 11060935

Group type: EXPERIMENTAL
Intervention: Exposure with counterconditioning (CC)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Regular one-session exposure (EXP)
Number of subjects: 34
Study: 9220094

Group type: EXPERIMENTAL
Intervention: Left Visual Field (LVF)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Right Visual Field (RVF)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: RVF
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: LVF
Number of subjects: 12
Study: 8477163

Group type: EXPERIMENTAL
Intervention: High umbilical arterial catheter position
Number of subjects: 308

Group type: COMPARATOR
Intervention: Low umbilical arterial catheter position
Number of subjects: 308
Study: 3718170

Group type: EXPERIMENTAL
Intervention: Neuroleptic treatment (double-blind placebo-controlled)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Withdrawal from neuroleptic treatment
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Neuroleptic treatment
Number of subjects: 27
Study: 31606226

Group type: EXPERIMENTAL
Intervention: Daily chewing gum (Arm A)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Standard care (Arm B)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Both arms (Arm A and Arm B)
Number of subjects: 91
Study: 29782907

Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen (ITB) bolus
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 27773665

Group type: EXPERIMENTAL
Intervention: Immediate ART
Number of subjects: 1026

Group type: COMPARATOR
Intervention: Deferred ART
Number of subjects: 1026
Study: 23946318

Group type: EXPERIMENTAL
Intervention: eletriptan 40 mg (ELE-40)
Number of subjects: 971

Group type: EXPERIMENTAL
Intervention: eletriptan 80 mg (ELE-80)
Number of subjects: 971

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 971
Study: 21903737

Group type: EXPERIMENTAL
Intervention: Aclidinium 400 μg bid
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tiotropium 8 μg once daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 20350669

Group type: EXPERIMENTAL
Intervention: Chiropractic care combined with exercise
Number of subjects: 20

Group type: COMPARATOR
Intervention: Exercise only
Number of subjects: 20
Study: 18367240

Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg PO daily for 1 week)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Allergen challenge
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lactated Ringer's solution challenge
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15897990

Group type: COMPARATOR
Intervention: nelfinavir
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir
Number of subjects: 653
Study: 12457377

Group type: EXPERIMENTAL
Intervention: d-chlorpheniramine (6 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10357448

Group type: COMPARATOR
Intervention: Artificial grammar learning
Number of subjects: 13

Group type: COMPARATOR
Intervention: Artificial grammar learning with transfer to novel lettersets
Number of subjects: 13

Group type: COMPARATOR
Intervention: Prototype learning
Number of subjects: 13
Study: 9121619

Group type: EXPERIMENTAL
Intervention: Treatment (not specified)
Number of subjects: 16
Study: 1988514

Group type: EXPERIMENTAL
Intervention: Cefotaxime, 2 g intravenously every 8 h (n = 16)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Ceftriaxone, 2 g intravenously every 24 h (n = 17)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Ceftriaxone or Cefotaxime
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 33
Study: 6349160

Group type: EXPERIMENTAL
Intervention: Arm-assisted step test (S)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Bicycle ergometer (B)
Number of subjects: 4
Study: 31489420

Group type: EXPERIMENTAL
Intervention: Minimally invasive technique (third generation chemical decaying technique plus traditional decaying method)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional decaying method
Number of subjects: 60
Study: 30856079

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (4000 IU daily for 2 months)
Number of subjects: 40
Study: 27707834

Group type: EXPERIMENTAL
Intervention: IPC/JIT device within lower limb cast
Number of subjects: 142
Study: 23827527

Group type: EXPERIMENTAL
Intervention: Multi-faceted influenza immunisation programme in intervention UMCs
Number of subjects: 3367

Group type: COMPARATOR
Intervention: Control UMCs
Number of subjects: 3367
Study: 22847969

Group type: EXPERIMENTAL
Intervention: DECISION+2 training program (2-hour online tutorial + 2-hour interactive seminar)
Number of subjects: 359

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: DECISION+2 training program
Number of subjects: 359

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 359
Study: 19773329

Group type: EXPERIMENTAL
Intervention: Arthritis self management programme plus education booklet
Number of subjects: 812

Group type: COMPARATOR
Intervention: Education booklet alone (standard care control group)
Number of subjects: 812
Study: 17355251

Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy (group 2)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Scleral buckling (group 1)
Number of subjects: 61
Study: 15197504

Group type: EXPERIMENTAL
Intervention: (11)C-metomidate (MTO)
Number of subjects: 16

Group type: COMPARATOR
Intervention: (18)F-fluorodeoxyglucose (FDG)
Number of subjects: 16
Study: 11144998

Group type: EXPERIMENTAL
Intervention: Tilidine (1.5 mg/kg) administered on the day of dialysis
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Tilidine (1.5 mg/kg) administered on a day in the dialysis-free interval
Number of subjects: 9

Group type: COMPARATOR
Intervention: Comparison with healthy volunteers
Number of subjects: 9